Search results for: 'detection ad next'

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...

This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast by segment, drivers and restraints, and technology trends, along with the competitive factors and strategies, and key companies to watch. The global market is primarily driven by the high prevalen...

Biomarkers are no longer mere tools used to measure the criteria of a biological process characteristic. They are being increasingly used in patient stratification and customised medical interventions. This research service presents an overview and analysis of the global biomarker market. It provides revenue forecasts for biomarker on technological...

The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of i...

This Frost Radar benchmarks companies offering digital pathology solutions for hospitals and laboratories and discusses opportunities in clinical, pharma, CRO, and research applications. Digital pathology solutions cover all aspects of workflow including sample collection and preparation, image acquisition and integrated image storage, and anal...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

10 Mar 2015  |  North America  |  Market Research

The US Blood Transfusion Diagnostics Market

Effective Strategies for Vendors to Tackle the Decrease in Blood Supply Demand

Infographics

×

This research study focuses on diagnostic tests performed on blood donor samples. The market segments are divided by blood grouping and disease screening and cover manual and automated instruments as well as reagents used for Abo and Rh testing, RBC antigen, and antibody identification and detection. Disease screening includes both serological and ...